During the past decade, Instituto Nacional del Torax conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 9 clinical trials were completed, i.e. on average, 112.5% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 7 clinical trials were completed. i.e. 175% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Instituto Nacional del Torax" #1 sponsor was "Boehringer Ingelheim" with 4 trials, followed by "Actelion" with 2 trials sponsored, "United Therapeutics" with 2 trials sponsored, "Cogentus Pharmaceuticals" with 1 trials sponsored and "Genomic Health®, Inc." with 1 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Instituto Nacional del Torax" #1 collaborator was "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)" with 1 trials as a collaborator, "Ankara University" with 1 trials as a collaborator, "Boehringer Ingelheim" with 1 trials as a collaborator, "Centre for Chronic Disease Control, India" with 1 trials as a collaborator and "Centre hospitalier de l'Université de Montréal (CHUM)" with 1 trials as a collaborator. Other collaborators include 8 different institutions and companies that were collaborators in the rest 18 trials.

According to Clinical.Site data, the most researched conditions in "Instituto Nacional del Torax" are "Pulmonary Arterial Hypertension" (4 trials), "Pulmonary Hypertension" (3 trials), "Cardiovascular Diseases" (2 trials), "Connective Tissue Diseases" (2 trials) and "Coronary Artery Disease" (2 trials). Many other conditions were trialed in "Instituto Nacional del Torax" in a lesser frequency.

Most popular intervention types in "Instituto Nacional del Torax" are "Drug" (10 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Nintedanib" (2 trials), "Ralinepag" (2 trials), "Ambrisentan" (1 trials) and "BI 1015550" (1 trials). Other intervention names were less common.

The vast majority of trials in "Instituto Nacional del Torax" are 16 trials for "All" genders.

Currently, there are NaN active trials in "Instituto Nacional del Torax". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 11 completed trials in Instituto Nacional del Torax, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Instituto Nacional del Torax, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".